Advertisement

Topics

Latest "Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia" News Stories

04:12 EDT 22nd March 2019 | BioPortfolio

Here are the most relevant search results for "Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia" found in our extensive news archives from over 250 global news sources.

More Information about Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia for you to read. Along with our medical data and news we also list Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia Clinical Trials, which are updated daily. BioPortfolio also has a large database of Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia Companies for you to search.

Showing "Alterations Plasma Proteome Early Onset Severe Preeclampsia" News Articles 1–25 of 8,100+

Thursday 21st March 2019

Reply to Comment on “Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy”


Comment on “Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy”

China urges subsidies to help disease-hit pig farms restock

China has urged rural governments to offer temporary subsidies to pig breeding farms and large-scale producers to help stabilize hog production, as fears grow about the impact of a severe disease outbreak on pork supplies.


BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease

STOCKHOLM, Sweden, March 21, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory study of BAN24...

CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009)

SUZHOU, China, March 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced that China's National Medical Products Administration (NMPA) has approved the clinical trial application to begin a Phase 1 trial in China for BLU-667 (CS3009), a highly selective and potent RET inhibitor discovered by CStone's partner Blueprint Medicines. The study is part of Blue...

Nippon Shinyaku gains exclusive Japanese rights to Zogenix's Fintepla

Nippon Shinyaku Co. Ltd. licensed exclusive Japanese commercialization rights to Zogenix Inc.'s Fintepla (fenfluramine; forme...

New Heart Failure Device Approved

The FDA has approved a device to treat chronic, moderate-to-severe heart failure in patients who aren't candidates for other HF devices. The Optimizer...

FDA Approves New Device for Chronic, Moderate-to-Severe Heart Failure

THURSDAY, March 21, 2019 -- The Optimizer Smart system was approved for treatment of patients with chronic, moderate-to-severe heart failure who are not eligible for treatment with other heart failure devices, including cardiac resynchronization...

Cryopreservation of immature testicular tissue leads to successful birth in monkeys

NIH-funded study is an early step in effort to maintain fertility of childhood cancer patients.

An acutely disturbed person in the community

It can be difficult to know what to do when a person in severe psychological distress presents to a general practice or community clinic, particularly if they are behaving aggressively, or if they are refusing help. Most patients who are acutely disturbed present no danger to others, however situations can evolve rapidly. Frontline staff need to...

Podcast: KHN’s ‘What The Health’ Surprise! Fixing Surprise Medical Bills Is Harder Than it Looks

Joanne Kenen of Politico, Anna Edney of Bloomberg News and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss the efforts to curb “surprise” medical bills to patients who inadvertently get out-of-network care; a look at where the 2020 presidential candidates stand on health; and the Trump administration’s efforts to end HIV in the U.S. Also, Rovner interviews Food and Dr...

New EnerFlex PROCARDO Boosts Circulation with Kyowa Quality® L-Citrulline & L-Arginine*

Ingredients improve Nitric Oxide production for beyond cholesterol regulation* NEW YORK (PRWEB) March 21, 2019 Inflammation is an enemy that attacks every part of the human body, including blood vessels. Arterial blockage, or atherosclerosis, is a biological condition directly linked to high LDL cholesterol levels. Regulating cholesterol helps, but consistent blood flow is critical to healthy art...

Early Career Investigators Program: Paving the way for future leaders

Dr Denis Lacombe speaks to ecancer at the 2019 EORTC General Annual Meeting (EGAM) about the significance of the Early Career Investigators (ECI) Program. Dr Lacombe explains the importance of this program which aims to develop and equip investigators...

Early Career Investigators Program: Mission and strategy

Dr Alexander van Akkooi speaks to ecancer at the 2019 EORTC General Annual Meeting (EGAM) about the strategy behind the Early Career Investigators (ECI) Program. Dr van Akkooi gives an overview of the ECI program, including its' mission and strategy in...

Early detection of oligometastatic disease

Dr Fréderic Lecouvet speaks to ecancer at the 2019 EORTC General Annual Meeting (EGAM) about the early systemic treatment of oligometastatic disease to improve patient outcomes. Dr Lecouvet also mentions the detection of early metastatic lesions and how...

Early Career Investigators Program: Structure and benefits

Prof Lugowska speaks to ecancer at the 2019 EORTC General Annual Meeting (EGAM) about the structure and advantages the Early Career Investigators (ECI) Program has provided for the EORTC and the wider medical community. Prof Lugowska elaborates on the...

Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update

Executed strategic agreement for Imeglimin with Roivant Sciences; potential for up to USD 600 million in regulatory and development milestone payments and sales-based payments plus royalties on net sales Roivant concurrently invested USD 15 million (approximately EUR 12 million) in Poxel through subscription in newly-issued ordinary ...

Interdisciplinary Study Club Launched by Acclaimed Periodontist in Torrance, CA, Dr. Arta Farahmand

Dr. Arta Farahmand, a periodontist in Torrance, CA, launches an interdisciplinary study club encouraging dental practitioners from a variety of specialties to work together and solve complex cases. Torrance, CA (PRWEB) March 21, 2019 Dr. Arta Farahmand, long-time periodontist in Torrance, CA, is leading a local study club aimed at bringing together periodontists, restorative clinicians, orthodont...

The evolution of brain tumours

Scientists from the German Cancer Research Center found in a recent study that only three different genetic alterations drive the early development of malignant glioblastomas. At least one of these three cancer drivers was present in all tumours...

NIH to test experimental drug to curb opioid cravings

Early stage trial opens at Clinical Center.

New Heart Failure Device Is Approved

THURSDAY, March 21, 2019 -- The Optimizer Smart System has been approved by the U.S. Food and Drug Administration for people with chronic, moderate-to-severe heart failure who are not candidates for other heart failure remedies. "Patients with...

Samsung Bioepis Announces Three-year Follow-up Data for Biosimilar Ontruzant in Early or Locally Advanced HER2-Positive Breast Cancer

INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. today announced findings of a three-year follow-up study comparing biosimilar ONTRUZANT® (trastuzumab) and reference medicine trastuzumab in early or locally advanced HER2-positive breast cancer. The data, which show comparable overall survival and cardiac safety, were presented today at the 16th St. Gallen International Br...

Premier Inc. Analysis: Hospital-Associated Sepsis Decreased by 15% from 2015-2018

Sepsis-related mortalities, readmissions and incidences decline as hospital efforts to save lives yield success, but hospital-associated cases are 10 percent more likely to progress to septic shock, leading to a 20 percent increase in the cost per case Healthcare providers are becoming more adept at preventing and treating the top cause of hospital dea...

Risk of MS Progression May Be Lessening Over Time (CME/CE)

(MedPage Today) -- Swedish study shows patients with relapsing onset MS are taking longer to reach disability milestones

GARNET Study Suggests Dostarlimab Promising for Uterine/Endometrial Cancer

Early phase clinical trial suggests Dostarlimab immunotherapy may advance treatment of endometrial cancer.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks